<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05100160</url>
  </required_header>
  <id_info>
    <org_study_id>2021-0653</org_study_id>
    <nct_id>NCT05100160</nct_id>
  </id_info>
  <brief_title>Gabapentin for the Reduction of Opiate Use Following Pulmonary Resection (GROUP Trial)</brief_title>
  <official_title>Gabapentin for the Reduction of Opiate Use Following Pulmonary Resection (GROUP Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to determine if the reduction in narcotic requirement following&#xD;
      pulmonary resection with gabapentin is clinically significant when compared to the effect&#xD;
      seen with placebo. We have defined clinically meaningful as a reduction by 30 Morphine&#xD;
      equivalent doses (MED)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Objectives:&#xD;
&#xD;
      The aim of this study is to determine if the reduction in narcotic requirement following&#xD;
      pulmonary resection with gabapentin is clinically significant when compared to the effect&#xD;
      seen with placebo. We have defined clinically meaningful as a reduction by 25% Morphine&#xD;
      equivalent doses (MED) Secondary objectives are to evaluate the utility of gabapentin in&#xD;
      reducing postoperative pain, reducing hospital length of stay, promoting faster return to&#xD;
      baseline function (to be assessed by MDASI), preventing post thoracotomy pain syndrome (to be&#xD;
      assessed by BPI), and reducing the rate of chronic opiate use among patients undergoing&#xD;
      thoracic procedures.&#xD;
&#xD;
        1. Primary Endpoint&#xD;
&#xD;
           The primary outcome will be the sum of the daily average morphine equivalent dose of&#xD;
           opioids recorded from day of surgery (day 0) through 7 days after surgery, for a total&#xD;
           of 8 days.&#xD;
&#xD;
        2. Secondary Endpoints&#xD;
&#xD;
             -  Time to resuming normal activities&#xD;
&#xD;
             -  Presence/absence of chronic pain at 3 and 6 months, measured by BPI&#xD;
&#xD;
             -  30, 90, 180 day opiate use (Y/N)&#xD;
&#xD;
             -  MDASI on post-operative days 7, 30, 90, 180&#xD;
&#xD;
             -  Basic Pain Inventory (BPI) on post-operative days 1,2, 7, 30, 90, 180&#xD;
&#xD;
             -  Daily pain score during hospitalization&#xD;
&#xD;
             -  Length of hospital stay&#xD;
&#xD;
             -  Need for opioids at discharge&#xD;
&#xD;
             -  Whether medication is stopped prior to day 25, and if so when and for what reason.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 30, 2022</start_date>
  <completion_date type="Anticipated">July 31, 2030</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2030</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change in narcotic requirement following pulmonary resection with gabapentin is clinically significant when compared to the effect seen with placebo</measure>
    <time_frame>through study completion, up to 8 days</time_frame>
    <description>The sum of the daily average morphine equivalent dose of opioids recorded from day of surgery (day 0) through 7 days after surgery, for a total of 8 days</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">448</enrollment>
  <condition>Thoracic</condition>
  <condition>Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>Gabapentin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>used as part of a multimodal pain regimen (combination of drugs used to control pain</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>designed to be compared with a study drug to learn if the study drug has any real effect</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gabapentin</intervention_name>
    <description>Given by PO</description>
    <arm_group_label>Gabapentin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Given by PO</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18+&#xD;
&#xD;
          -  Undergoing pulmonary resection (includes metastasectomy as well as anatomic&#xD;
             resections)&#xD;
&#xD;
          -  Must have device with email capabilities for follow up survey&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Requiring narcotic pain medication or Gabapentin at the time of preoperative&#xD;
             appointment or within 30 days of surgery&#xD;
&#xD;
          -  Renal impairment requiring dialysis&#xD;
&#xD;
          -  Allergy to Gabapentin&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Rice</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Rice</last_name>
    <phone>(713) 563-9153</phone>
    <email>drice@mdanderson.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>David Rice</last_name>
      <phone>713-563-9153</phone>
      <email>drice@mdanderson.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>M D Anderson Cancer Center</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 22, 2021</study_first_submitted>
  <study_first_submitted_qc>October 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2021</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gabapentin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

